Zynyz (retifanlimab-dlwr) — Medica
Merkel cell carcinoma, metastatic or locally advanced
Initial criteria
- age ≥ 18 years
- ONE of the following: (i) primary or recurrent locally advanced disease where curative surgery and curative radiation are not feasible; OR (ii) primary or recurrent regional disease where curative surgery and curative radiation are not feasible; OR (iii) metastatic disease
- prescribed by or in consultation with an oncologist
Approval duration
1 year